Acute Myeloid Leukemia
Sutro Biopharma Inc. is involved in clinical research for acute myeloid leukemia, with attention to treatment options for infants and children under 12 years of age. The company’s oncology portfolio includes evaluation of luveltamab tazevibulin in this hematologic malignancy.
- Pediatric AML
- Luveltamab tazevibulin
- Hematologic oncology
The sponsor’s work in this area reflects interest in targeted approaches for difficult-to-treat leukemia populations.
Advanced Epithelial Ovarian Cancer
The sponsor funds clinical studies in advanced epithelial ovarian cancer, including fallopian tube cancer and primary peritoneal cancer. Research activity also includes tumors expressing FOLR1, with investigation of luveltamab tazevibulin as a therapeutic candidate.
- FOLR1-expressing disease
- Fallopian tube cancer
- Primary peritoneal cancer
This area centers on gynecologic malignancies with a focus on biomarker-linked treatment selection.
Antibody-Drug Conjugate Oncology
Sutro Biopharma Inc. has a strong interest in antibody-drug conjugates, particularly STRO-002 and luveltamab tazevibulin, across solid and hematologic tumors. Its clinical program includes combinations with bevacizumab and comparisons with chemotherapy regimens.
- STRO-002
- Bevacizumab combinations
- Comparator chemotherapy
The research portfolio is concentrated on targeted oncology therapies linked to folate receptor alpha biology.
